Hussain Naveed, Rosenkrantz Ted S
Division of Neonatology, Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT 06030-2948, USA.
Semin Perinatol. 2003 Dec;27(6):458-70. doi: 10.1053/j.semperi.2003.10.005.
With ongoing improvements in technology and the understanding of neonatal physiology, there has been increasing debate regarding the gestational age and birth weight limits of an infants' capability of sustaining life outside the womb and how this is to be determined. The objective of this review was to address this issue with an analysis of current data (following the introduction of surfactant therapy in 1990) from published studies of survival in extremely low gestational age infants. We found that survival was possible at 22 completed weeks of gestation but only in < 4% of live births reported. Survival increased from 21% at 23 weeks gestational age to 46% at 24 weeks gestational age. Historically, despite continual advances in neonatology, the mortality at 22 weeks has not improved over the past three decades. Combining the data from studies on survival with evidence from developmental biology, we believe that it is not worthwhile to pursue aggressive support of infants born at < 23 weeks gestational age. Given the complicated issues related to morbidity and mortality in infants born at 22 to 25 weeks gestational age and the ethical implications of the available evidence, we propose the need for a consensus derived framework to help in decision-making.
随着技术的不断进步以及对新生儿生理学认识的加深,关于婴儿在子宫外维持生命能力的胎龄和出生体重限制以及如何确定这些限制的争论日益激烈。本综述的目的是通过分析已发表的极低胎龄婴儿生存研究的当前数据(1990年引入表面活性剂治疗之后)来解决这一问题。我们发现,妊娠22足周时婴儿有可能存活,但在所报道的活产婴儿中比例不到4%。存活率从孕23周时的21%升至孕24周时的46%。从历史上看,尽管新生儿学不断取得进展,但在过去三十年里,孕22周时的死亡率并未改善。综合生存研究数据与发育生物学证据,我们认为,对孕23周前出生的婴儿进行积极支持并不值得。鉴于孕22至25周出生婴儿的发病率和死亡率相关的复杂问题以及现有证据的伦理意义,我们建议需要一个达成共识的框架来帮助进行决策。